Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isa-Pd in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple Myeloma
NCT05911321Phase 2Active, not recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Dec 2023
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab, pomalidomide, dexamethasone in multiple myeloma (MM), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Dec 2023; status: active, not recruiting.
02
Drugs
isatuximabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05911321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911321.